207 related articles for article (PubMed ID: 35822558)
21. The sonic hedgehog signaling pathway maintains the cancer stem cell self-renewal of anaplastic thyroid cancer by inducing snail expression.
Heiden KB; Williamson AJ; Doscas ME; Ye J; Wang Y; Liu D; Xing M; Prinz RA; Xu X
J Clin Endocrinol Metab; 2014 Nov; 99(11):E2178-87. PubMed ID: 25078145
[TBL] [Abstract][Full Text] [Related]
22. A novel therapeutic approach for anaplastic thyroid cancer through inhibition of LAT1.
Enomoto K; Sato F; Tamagawa S; Gunduz M; Onoda N; Uchino S; Muragaki Y; Hotomi M
Sci Rep; 2019 Oct; 9(1):14616. PubMed ID: 31601917
[TBL] [Abstract][Full Text] [Related]
23. Regulation of cancer stem cell activity by thyroid hormone receptor β.
Lee WK; Zhu X; Park S; Zhu YJ; Zhao L; Meltzer P; Cheng SY
Oncogene; 2022 Apr; 41(16):2315-2325. PubMed ID: 35256781
[TBL] [Abstract][Full Text] [Related]
24. Phenotypic characterization of metastatic anaplastic thyroid cancer stem cells.
Li W; Reeb AN; Sewell WA; Elhomsy G; Lin RY
PLoS One; 2013; 8(5):e65095. PubMed ID: 23724124
[TBL] [Abstract][Full Text] [Related]
25. Steroid receptor coactivator-3 as a target for anaplastic thyroid cancer.
Lee WK; Kim WG; Fozzatti L; Park S; Zhao L; Willingham MC; Lonard D; O'Malley BW; Cheng SY
Endocr Relat Cancer; 2020 Apr; 27(4):209-220. PubMed ID: 31977311
[TBL] [Abstract][Full Text] [Related]
26. Torin2 targets dysregulated pathways in anaplastic thyroid cancer and inhibits tumor growth and metastasis.
Sadowski SM; Boufraqech M; Zhang L; Mehta A; Kapur P; Zhang Y; Li Z; Shen M; Kebebew E
Oncotarget; 2015 Jul; 6(20):18038-49. PubMed ID: 25945839
[TBL] [Abstract][Full Text] [Related]
27. Targeting CDK12-mediated transcription regulation in anaplastic thyroid carcinoma.
Geng M; Yang Y; Cao X; Dang L; Zhang T; Zhang L
Biochem Biophys Res Commun; 2019 Dec; 520(3):544-550. PubMed ID: 31615655
[TBL] [Abstract][Full Text] [Related]
28. Resveratrol Suppresses the Growth and Enhances Retinoic Acid Sensitivity of Anaplastic Thyroid Cancer Cells.
Li YT; Tian XT; Wu ML; Zheng X; Kong QY; Cheng XX; Zhu GW; Liu J; Li H
Int J Mol Sci; 2018 Mar; 19(4):. PubMed ID: 29596381
[TBL] [Abstract][Full Text] [Related]
29. Apatinib Inhibits Angiogenesis Via Suppressing Akt/GSK3β/ANG Signaling Pathway in Anaplastic Thyroid Cancer.
Jin Z; Cheng X; Feng H; Kuang J; Yang W; Peng C; Shen B; Qiu W
Cell Physiol Biochem; 2017; 44(4):1471-1484. PubMed ID: 29190616
[TBL] [Abstract][Full Text] [Related]
30. Resveratrol and its Nanoparticle suppress Doxorubicin/Docetaxel-resistant anaplastic Thyroid Cancer Cells
Xiong L; Lin XM; Nie JH; Ye HS; Liu J
Nanotheranostics; 2021; 5(2):143-154. PubMed ID: 33457193
[No Abstract] [Full Text] [Related]
31. The LAT1 inhibitor JPH203 reduces growth of thyroid carcinoma in a fully immunocompetent mouse model.
Häfliger P; Graff J; Rubin M; Stooss A; Dettmer MS; Altmann KH; Gertsch J; Charles RP
J Exp Clin Cancer Res; 2018 Sep; 37(1):234. PubMed ID: 30241549
[TBL] [Abstract][Full Text] [Related]
32. Thyroid hormone receptor α1: a novel regulator of thyroid cancer cell differentiation.
Hwang E; Doolittle WKL; Zhu YJ; Zhu X; Zhao L; Yu Y; Cheng SY
Oncogene; 2023 Oct; 42(41):3075-3086. PubMed ID: 37634007
[TBL] [Abstract][Full Text] [Related]
33. Alantolactone induces concurrent apoptosis and GSDME-dependent pyroptosis of anaplastic thyroid cancer through ROS mitochondria-dependent caspase pathway.
Hu Y; Wen Q; Cai Y; Liu Y; Ma W; Li Q; Song F; Guo Y; Zhu L; Ge J; Zeng Q; Wang J; Yin C; Zheng G; Ge M
Phytomedicine; 2023 Jan; 108():154528. PubMed ID: 36343549
[TBL] [Abstract][Full Text] [Related]
34. KLF5 influences cell biological function and chemotherapy sensitivity through the JNK signaling pathway in anaplastic thyroid carcinoma.
Wang Z; Qiu X; Zhang H; Li W
J Biochem Mol Toxicol; 2020 May; 34(5):e22469. PubMed ID: 32173973
[TBL] [Abstract][Full Text] [Related]
35. Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo.
Ferrari SM; Bocci G; Di Desidero T; Elia G; Ruffilli I; Ragusa F; Orlandi P; Paparo SR; Patrizio A; Piaggi S; La Motta C; Ulisse S; Baldini E; Materazzi G; Miccoli P; Antonelli A; Fallahi P
Oncol Rep; 2018 May; 39(5):2225-2234. PubMed ID: 29517103
[TBL] [Abstract][Full Text] [Related]
36. Laminin-5γ-2 (LAMC2) is highly expressed in anaplastic thyroid carcinoma and is associated with tumor progression, migration, and invasion by modulating signaling of EGFR.
Garg M; Kanojia D; Okamoto R; Jain S; Madan V; Chien W; Sampath A; Ding LW; Xuan M; Said JW; Doan NB; Liu LZ; Yang H; Gery S; Braunstein GD; Koeffler HP
J Clin Endocrinol Metab; 2014 Jan; 99(1):E62-72. PubMed ID: 24170107
[TBL] [Abstract][Full Text] [Related]
37. MADD silencing enhances anti-tumor activity of TRAIL in anaplastic thyroid cancer.
Saini S; Sripada L; Tulla K; Qiao G; Kunda N; Maker AV; Prabhakar BS
Endocr Relat Cancer; 2019 Jun; 26(6):551-563. PubMed ID: 30999276
[TBL] [Abstract][Full Text] [Related]
38. Targeting MYC as a Therapeutic Intervention for Anaplastic Thyroid Cancer.
Enomoto K; Zhu X; Park S; Zhao L; Zhu YJ; Willingham MC; Qi J; Copland JA; Meltzer P; Cheng SY
J Clin Endocrinol Metab; 2017 Jul; 102(7):2268-2280. PubMed ID: 28368473
[TBL] [Abstract][Full Text] [Related]
39. SOX13/TRIM11/YAP axis promotes the proliferation, migration and chemoresistance of anaplastic thyroid cancer.
Tang J; Tian Z; Liao X; Wu G
Int J Biol Sci; 2021; 17(2):417-429. PubMed ID: 33613102
[TBL] [Abstract][Full Text] [Related]
40. S100A8 is a novel therapeutic target for anaplastic thyroid carcinoma.
Reeb AN; Li W; Sewell W; Marlow LA; Tun HW; Smallridge RC; Copland JA; Spradling K; Chernock R; Lin RY
J Clin Endocrinol Metab; 2015 Feb; 100(2):E232-42. PubMed ID: 25423568
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
